Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

Nicole A Shonka, Yuji Piao, Mark Gilbert, Alfred Yung, Susan Chang, Lisa M. Deangelis, Andrew B. Lassman, Jun Liu, Timothy Cloughesy, H. Ian Robins, Rita Lloyd, Alice Chen, Michael Prados, Patrick Y. Wen, John Heymach, John De Groot

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Plasma profiling of patients treated with antiangiogenic agents may identify markers that correlate with toxicity. Objectives were to correlate changes in cytokine and angiogenic factors as potential markers of toxicity to aflibercept. Circulating cytokine and angiogenic factors were measured in 28 patients with recurrent glioblastoma in a single-arm phase II study of aflibercept. Plasma samples were analyzed at baseline, 24 h, and 28 days using multiplex assays or ELISA. We evaluated log-transformed baseline biomarker expressions with Cox proportional hazard regression models to assess the effect of markers on any grade II-IV (Gr II-IV) toxicity, on-target toxicity (hypertension, proteinuria, thromboembolism), and fatigue. All tests were two sided with a statistical significance level of p = 0.05. Among 28 pts, there were 116 Gr II-IV events. Changes in IL-13 from baseline to 24 h predicted on-target toxicities. Increases in IL-1b, IL-6, and IL-10 at 24 h were significantly associated with fatigue. Progression-free survival was 14.9 months for patients in the all-toxicity group and 9.0 months for patients in the on-target toxicity group compared to 4.3 months for those who did not develop any Gr II-IV toxicity (p = 0.002 and p = 0.045, respectively). Toxicity from antiangiogenic therapy remains an important cause of antiangiogenic treatment discontinuation and patient morbidity. Changes in IL6, IL10, and IL13 were repeatedly correlated with toxicity. Profiling of IL-13 as a surrogate for endothelial dysfunction could individualize patients at risk during antiangiogenic therapy, as could identifying those at higher risk for fatigue using IL-6 and IL-10.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalTargeted Oncology
Volume8
Issue number2
DOIs
StatePublished - Jun 1 2013

Fingerprint

Glioblastoma
Cytokines
Interleukin-13
Interleukin-10
Fatigue
Interleukin-6
Angiogenesis Inducing Agents
Therapeutics
Angiogenesis Inhibitors
Thromboembolism
Proteinuria
Proportional Hazards Models
Disease-Free Survival
aflibercept
Biomarkers
Enzyme-Linked Immunosorbent Assay
Hypertension
Morbidity

Keywords

  • Aflibercept
  • Cytokines
  • Glioblastoma
  • Toxicity
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. / Shonka, Nicole A; Piao, Yuji; Gilbert, Mark; Yung, Alfred; Chang, Susan; Deangelis, Lisa M.; Lassman, Andrew B.; Liu, Jun; Cloughesy, Timothy; Robins, H. Ian; Lloyd, Rita; Chen, Alice; Prados, Michael; Wen, Patrick Y.; Heymach, John; De Groot, John.

In: Targeted Oncology, Vol. 8, No. 2, 01.06.2013, p. 117-125.

Research output: Contribution to journalArticle

Shonka, NA, Piao, Y, Gilbert, M, Yung, A, Chang, S, Deangelis, LM, Lassman, AB, Liu, J, Cloughesy, T, Robins, HI, Lloyd, R, Chen, A, Prados, M, Wen, PY, Heymach, J & De Groot, J 2013, 'Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept', Targeted Oncology, vol. 8, no. 2, pp. 117-125. https://doi.org/10.1007/s11523-013-0254-0
Shonka, Nicole A ; Piao, Yuji ; Gilbert, Mark ; Yung, Alfred ; Chang, Susan ; Deangelis, Lisa M. ; Lassman, Andrew B. ; Liu, Jun ; Cloughesy, Timothy ; Robins, H. Ian ; Lloyd, Rita ; Chen, Alice ; Prados, Michael ; Wen, Patrick Y. ; Heymach, John ; De Groot, John. / Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. In: Targeted Oncology. 2013 ; Vol. 8, No. 2. pp. 117-125.
@article{9bc750f01fc94fdcb3e3df6b6d9ddb0c,
title = "Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept",
abstract = "Plasma profiling of patients treated with antiangiogenic agents may identify markers that correlate with toxicity. Objectives were to correlate changes in cytokine and angiogenic factors as potential markers of toxicity to aflibercept. Circulating cytokine and angiogenic factors were measured in 28 patients with recurrent glioblastoma in a single-arm phase II study of aflibercept. Plasma samples were analyzed at baseline, 24 h, and 28 days using multiplex assays or ELISA. We evaluated log-transformed baseline biomarker expressions with Cox proportional hazard regression models to assess the effect of markers on any grade II-IV (Gr II-IV) toxicity, on-target toxicity (hypertension, proteinuria, thromboembolism), and fatigue. All tests were two sided with a statistical significance level of p = 0.05. Among 28 pts, there were 116 Gr II-IV events. Changes in IL-13 from baseline to 24 h predicted on-target toxicities. Increases in IL-1b, IL-6, and IL-10 at 24 h were significantly associated with fatigue. Progression-free survival was 14.9 months for patients in the all-toxicity group and 9.0 months for patients in the on-target toxicity group compared to 4.3 months for those who did not develop any Gr II-IV toxicity (p = 0.002 and p = 0.045, respectively). Toxicity from antiangiogenic therapy remains an important cause of antiangiogenic treatment discontinuation and patient morbidity. Changes in IL6, IL10, and IL13 were repeatedly correlated with toxicity. Profiling of IL-13 as a surrogate for endothelial dysfunction could individualize patients at risk during antiangiogenic therapy, as could identifying those at higher risk for fatigue using IL-6 and IL-10.",
keywords = "Aflibercept, Cytokines, Glioblastoma, Toxicity, VEGF",
author = "Shonka, {Nicole A} and Yuji Piao and Mark Gilbert and Alfred Yung and Susan Chang and Deangelis, {Lisa M.} and Lassman, {Andrew B.} and Jun Liu and Timothy Cloughesy and Robins, {H. Ian} and Rita Lloyd and Alice Chen and Michael Prados and Wen, {Patrick Y.} and John Heymach and {De Groot}, John",
year = "2013",
month = "6",
day = "1",
doi = "10.1007/s11523-013-0254-0",
language = "English (US)",
volume = "8",
pages = "117--125",
journal = "Targeted Oncology",
issn = "1776-2596",
publisher = "Springer Paris",
number = "2",

}

TY - JOUR

T1 - Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept

AU - Shonka, Nicole A

AU - Piao, Yuji

AU - Gilbert, Mark

AU - Yung, Alfred

AU - Chang, Susan

AU - Deangelis, Lisa M.

AU - Lassman, Andrew B.

AU - Liu, Jun

AU - Cloughesy, Timothy

AU - Robins, H. Ian

AU - Lloyd, Rita

AU - Chen, Alice

AU - Prados, Michael

AU - Wen, Patrick Y.

AU - Heymach, John

AU - De Groot, John

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Plasma profiling of patients treated with antiangiogenic agents may identify markers that correlate with toxicity. Objectives were to correlate changes in cytokine and angiogenic factors as potential markers of toxicity to aflibercept. Circulating cytokine and angiogenic factors were measured in 28 patients with recurrent glioblastoma in a single-arm phase II study of aflibercept. Plasma samples were analyzed at baseline, 24 h, and 28 days using multiplex assays or ELISA. We evaluated log-transformed baseline biomarker expressions with Cox proportional hazard regression models to assess the effect of markers on any grade II-IV (Gr II-IV) toxicity, on-target toxicity (hypertension, proteinuria, thromboembolism), and fatigue. All tests were two sided with a statistical significance level of p = 0.05. Among 28 pts, there were 116 Gr II-IV events. Changes in IL-13 from baseline to 24 h predicted on-target toxicities. Increases in IL-1b, IL-6, and IL-10 at 24 h were significantly associated with fatigue. Progression-free survival was 14.9 months for patients in the all-toxicity group and 9.0 months for patients in the on-target toxicity group compared to 4.3 months for those who did not develop any Gr II-IV toxicity (p = 0.002 and p = 0.045, respectively). Toxicity from antiangiogenic therapy remains an important cause of antiangiogenic treatment discontinuation and patient morbidity. Changes in IL6, IL10, and IL13 were repeatedly correlated with toxicity. Profiling of IL-13 as a surrogate for endothelial dysfunction could individualize patients at risk during antiangiogenic therapy, as could identifying those at higher risk for fatigue using IL-6 and IL-10.

AB - Plasma profiling of patients treated with antiangiogenic agents may identify markers that correlate with toxicity. Objectives were to correlate changes in cytokine and angiogenic factors as potential markers of toxicity to aflibercept. Circulating cytokine and angiogenic factors were measured in 28 patients with recurrent glioblastoma in a single-arm phase II study of aflibercept. Plasma samples were analyzed at baseline, 24 h, and 28 days using multiplex assays or ELISA. We evaluated log-transformed baseline biomarker expressions with Cox proportional hazard regression models to assess the effect of markers on any grade II-IV (Gr II-IV) toxicity, on-target toxicity (hypertension, proteinuria, thromboembolism), and fatigue. All tests were two sided with a statistical significance level of p = 0.05. Among 28 pts, there were 116 Gr II-IV events. Changes in IL-13 from baseline to 24 h predicted on-target toxicities. Increases in IL-1b, IL-6, and IL-10 at 24 h were significantly associated with fatigue. Progression-free survival was 14.9 months for patients in the all-toxicity group and 9.0 months for patients in the on-target toxicity group compared to 4.3 months for those who did not develop any Gr II-IV toxicity (p = 0.002 and p = 0.045, respectively). Toxicity from antiangiogenic therapy remains an important cause of antiangiogenic treatment discontinuation and patient morbidity. Changes in IL6, IL10, and IL13 were repeatedly correlated with toxicity. Profiling of IL-13 as a surrogate for endothelial dysfunction could individualize patients at risk during antiangiogenic therapy, as could identifying those at higher risk for fatigue using IL-6 and IL-10.

KW - Aflibercept

KW - Cytokines

KW - Glioblastoma

KW - Toxicity

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84878798318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878798318&partnerID=8YFLogxK

U2 - 10.1007/s11523-013-0254-0

DO - 10.1007/s11523-013-0254-0

M3 - Article

C2 - 23345034

AN - SCOPUS:84878798318

VL - 8

SP - 117

EP - 125

JO - Targeted Oncology

JF - Targeted Oncology

SN - 1776-2596

IS - 2

ER -